Literature DB >> 23569320

Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.

Emmanuel S Antonarakis, Mario A Eisenberger.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23569320      PMCID： PMC4812821          DOI： 10.1200/JCO.2013.48.8825

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

1.  Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.

Authors:  Donald L Trump; Heather Payne; Kurt Miller; Johann S de Bono; Joe Stephenson; Howard A Burris; Faith Nathan; Maria Taboada; Thomas Morris; Andreas Hubner
Journal:  Prostate       Date:  2011-01-26       Impact factor: 4.104

2.  Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.

Authors:  Howard I Scher; Xiaoyu Jia; Kim Chi; Ronald de Wit; William R Berry; Peter Albers; Brian Henick; David Waterhouse; Dean J Ruether; Peter J Rosen; Anthony A Meluch; Luke T Nordquist; Peter M Venner; Axel Heidenreich; Luis Chu; Glenn Heller
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

3.  Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

Authors:  Kim N Chi; Sebastien J Hotte; Evan Y Yu; Dongsheng Tu; Bernhard J Eigl; Ian Tannock; Fred Saad; Scott North; Jean Powers; Martin E Gleave; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2010-08-23       Impact factor: 44.544

Review 4.  End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.

Authors:  Howard I Scher; Michael J Morris; Ethan Basch; Glenn Heller
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

5.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Authors:  William Kevin Kelly; Susan Halabi; Michael Carducci; Daniel George; John F Mahoney; Walter M Stadler; Michael Morris; Philip Kantoff; J Paul Monk; Ellen Kaplan; Nicholas J Vogelzang; Eric J Small
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

6.  Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.

Authors:  Nicholas D James; Armelle Caty; Heather Payne; Michael Borre; Bernard A Zonnenberg; Philippe Beuzeboc; Stuart McIntosh; Thomas Morris; De Phung; Nancy A Dawson
Journal:  BJU Int       Date:  2010-10       Impact factor: 5.588

7.  Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.

Authors:  John C Araujo; Paul Mathew; Andrew J Armstrong; Edward L Braud; Edwin Posadas; Mathew Lonberg; Gary E Gallick; Géralyn C Trudel; Prashni Paliwal; Shruti Agrawal; Christopher J Logothetis
Journal:  Cancer       Date:  2011-07-25       Impact factor: 6.860

8.  A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.

Authors:  Andrew J Armstrong; Patricia Creel; James Turnbull; Cassandra Moore; Tracy A Jaffe; Sherri Haley; William Petros; Sarah Yenser; Jon P Gockerman; Darryl Sleep; Herbert Hurwitz; Daniel J George
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

Authors:  Karim Fizazi; Karim S Fizazi; Celestia S Higano; Joel B Nelson; Martin Gleave; Kurt Miller; Thomas Morris; Faith E Nathan; Stuart McIntosh; Kristine Pemberton; Judd W Moul
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544
View more
  19 in total

1.  Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale.

Authors:  Ramy Sedhom; Emmanuel S Antonarakis
Journal:  Transl Androl Urol       Date:  2019-07

2.  The STAMPEDE trial: paradigm-changing data through innovative trial design.

Authors:  Bradley C Carthon; Emmanuel S Antonarakis
Journal:  Transl Cancer Res       Date:  2016-09       Impact factor: 1.241

3.  Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.

Authors:  Joseph Kattan; Marwan Bachour; Fadi Farhat; Elie El Rassy; Tarek Assi; Marwan Ghosn
Journal:  Invest New Drugs       Date:  2016-05-10       Impact factor: 3.850

Review 4.  Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.

Authors:  Aurelius Omlin; Carmel Pezaro; Silke Gillessen Sommer
Journal:  Ther Adv Urol       Date:  2014-02

5.  High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.

Authors:  Adam T Szafran; Cliff Stephan; Michael Bolt; Maureen G Mancini; Marco Marcelli; Michael A Mancini
Journal:  Prostate       Date:  2016-10-04       Impact factor: 4.104

6.  Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer.

Authors:  Ashish Ranjan; Compton J Benjamin; Ayele H Negussie; Saurin Chokshi; Paul H Chung; Dmitry Volkin; Nitin Yeram; W Marston Linehan; Matthew R Dreher; Peter A Pinto; Bradford J Wood
Journal:  Pharm Res       Date:  2016-06-24       Impact factor: 4.200

Review 7.  Immunotherapy for Prostate Cancer.

Authors:  Nicholas J Venturini; Charles G Drake
Journal:  Cold Spring Harb Perspect Med       Date:  2019-05-01       Impact factor: 6.915

8.  Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin.

Authors:  J G C van Hasselt; A Gupta; Z Hussein; J H Beijnen; J H M Schellens; A D R Huitema
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-30

9.  The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.

Authors:  A P Toner; F McLaughlin; F J Giles; F J Sullivan; E O'Connell; L A Carleton; L Breen; G Dunne; A M Gorman; J D Lewis; S A Glynn
Journal:  Br J Cancer       Date:  2013-09-19       Impact factor: 7.640

10.  Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.

Authors:  Ravi A Madan; Fatima H Karzai; Munjid Al Harthy; Daniel P Petrylak; Joseph W Kim; Philip M Arlen; Inger Rosner; Marc R Theoret; Lisa Cordes; Marijo Bilusic; Cody J Peer; Nancy A Dawson; Anna Couvillon; Amy Hankin; Moniquea Williams; Guin Chun; Helen Owens; Jennifer L Marte; Min-Jung Lee; Yusuke Tomita; Akira Yuno; Jane B Trepel; Sunmin Lee; Seth M Steinberg; James L Gulley; William D Figg; William L Dahut
Journal:  BJU Int       Date:  2020-10-23       Impact factor: 5.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.